NASDAQ: BLTE - Belite Bio, Inc

Yield per half year: +81.24%
Sector: Healthcare

Share chart Belite Bio, Inc

Extended chart Simple chart
Financial Markets by TradingView

About

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients.

More details
The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Цена ао 67.55
EBITDA -0.0057
Число акций ао 0.02659 млрд
P/BV 14.39
EV/EBITDA -1.08
ISIN US07782B1044
Сайт https://belitebio.com
Валюта usd
IPO date 2022-04-29
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: +1.41% (66.61)
Change price per week: +21.06% (55.8)
Change price per month: +39.13% (48.55)
Change price per 3 month: +34.83% (50.1)
Change price per half year: +81.24% (37.27)
Change price per year: +84.66% (36.58)
Change price per year to date: +79.13% (37.71)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 13.5 1
P/E 0 0
EV/EBITDA -36.24 0
Total: 1.13

Efficiency

Title Value Grade
ROA, % -33.42 0
ROE, % -34.98 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0283 10
Total: 9

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 448.58 10
Yield EPS, % 398.1 10
Total: 8
More

Institutions Volume Share, %
Armistice Capital, LLC 36000 0.12
Morgan Stanley 22421 0.08
State Street Corporation 17557 0.06
Cubist Systematic Strategies, LLC 16882 0.06
Marshall Wace LLP 16011 0.05
JP Morgan Chase & Company 14267 0.05
Point72 Asset Management, L.P. 7700 0.03
Geode Capital Management, LLC 6700 0.02
Jump Financial, LLC 5200 0.02
Renaissance Technologies, LLC 4900 0.02

ETF Share, % Profitability for 1 year, % Dividends, %
Virtus LifeSci Biotech Clinical Trials ETF 0.76712 63.040315712071 0.33
SPDR S&P Emerging Markets Small Cap ETF 0.03878 9.4592150479291 3.03583
SPDR S&P China ETF 0.02029 5.8641975308642 3.40103
SPDR Portfolio Emerging Markets ETF 0.00475 13.575967648758 3.1879



Head Job title Payment Year of birth
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO N/A 1979 (45 years)
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director N/A 1985 (39 years)
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer N/A 1967 (57 years)
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board

Address: United States, San Diego. CA, 12750 High Bluff Drive - open in Google maps, open in Yandex maps
Website: https://belitebio.com